Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar;77(3):390-2.
doi: 10.1136/jnnp.2005.072660.

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population

Affiliations

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population

A Czaplinski et al. J Neurol Neurosurg Psychiatry. 2006 Mar.

Abstract

In a large cohort of 1034 patients with the diagnosis of definite or probable amyotrophic lateral sclerosis (ALS), the association of forced vital capacity (FVC) at baseline with (a) time to progression of 20 points in Appel ALS (AALS) score or (b) tracheostomy free survival was investigated. The median survival of ALS patients with baseline FVC <75% was 2.91 years, compared with 4.08 years for patients with baseline FVC >75% (p<0.001). Patients with baseline FVC <75% progressed more rapidly (taking 8.0 months to progress 20 AALS points) compared with patients with baseline FVC >75% (10.0 months, p<0.001). Moreover, FVC at first examination was identified as a significant predictor of survival and disease progression in both univariate and multivariate Cox regression models, after adjustment for age, sex, site of onset, diagnostic delay, riluzole therapy, and use of bilateral positive airway pressure and percutaneous endoscopic gastrostomy (p<0.001). We conclude that a single FVC value obtained at an initial visit may serve as a clinically meaningful predictor of survival and disease progression in ALS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: none

References

    1. Traynor B J, Zhang H, Shefner J M.et al Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004631933–1935. - PubMed
    1. Caroscio J T, Mulvihill M N, Sterling R.et al Amyotrophic lateral sclerosis: its natural history. Neurol Clin 198751–8. - PubMed
    1. Kleopa K A, Sherman M, Neal B.et al Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 199916482–88. - PubMed
    1. Haverkamp L J, Appel V, Appel S H. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995118707–719. - PubMed
    1. Miller R G, Munsat T L, Swash M.et al Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci 19991692–12. - PubMed

Publication types